Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: Findings from the prostate testing for cancer and treatment study and a systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 2874-2881

  Chen, Lina ^a   Smith, George Davey ^a   Evans, David M ^a   Cox, Angela ^b   Lawlor, Debbie A ^a   Donovan, Jenny ^a   Yuan, Wei ^a   Day, Ian N M ^a   Martin, Richard M ^a   Lane, Athene ^a   Rodriguez, Santi ^a   Davis, Michael ^a   Zuccolo, Luisa ^a   Collin, Simon M ^a   Hamdy, Freddie ^c   Neal, David ^d   Lewis, Sarah J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BSMI PROTEIN; FOKI PROTEIN; REGULATOR PROTEIN; RESTRICTION ENDONUCLEASE; SERINE PROTEINASE INHIBITOR; TAQI PROTEIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; DISEASE SEVERITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

AGED; DNA RESTRICTION ENZYMES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 72749127108     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0544     Document Type: Article

References (49)

1. Apperly FL. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941;1:191-195
2. 3 and prostate cancer cell proliferation in vivo. Urology 1995;46:365-369
3. Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006;26:2525-2530 (Pubitemid 44155531)
4. Krishnan AV, Swami S, Moreno J, et al. Potentiation of the growthinhibitory effects of vitamin D in prostate cancer by genistein. Nutr Rev 2007;65:S121-3.
5. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467-472
6. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000;86:40-46 (Pubitemid 30133984)
7. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 1995;6:235-239
8. Gann PH, Ma J, Hennekens CH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:121-126
9. Nomura AM, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-432 (Pubitemid 28466695)
10. Jacobs ET, Giuliano AR, Martinez ME, et al. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89-90:533-537
11. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-265 (Pubitemid 38988034)
12. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-108 (Pubitemid 37444451)
13. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4:e103.
14. Mikhak B, Hunter DJ, Spiegelman D, et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 2007;67:911-923 (Pubitemid 46828925)
15. BrawerMK.Recent progress in the treatment of advanced prostate cancer with intermittent dose-intense calcitriol (DN-101). Rev Urol 2007;9:1-8.
16. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25:669-674
17. Ogunkolade WB, Boucher BJ, Bustin SA, et al. Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing "betel nut" (Areca catechu) and vitamin D status. J Clin Endocrinol Metab 2006;91:2612-2617
18. 3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 2004;92:317-325 (Pubitemid 40128252)
19. Arai H, Miyamoto KI, Yoshida M, et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 2001;16:1256-1264 (Pubitemid 32574654)
20. Jurutka PW, Remus LS, Whitfield GK, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 2000;14:401-420
21. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-287 (Pubitemid 24051146)
22. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
23. Davey Smith G, Lawlor DA, Harbord R, et al. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med 2007;4:e352.
24. Blazer DG III, Umbach DM, Bostick RM, Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog 2000;27:18-23. (Pubitemid 30089999)
25. Cicek MS, Liu X, Schumacher FR, Casey G, Witte JS. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:2549-2552 (Pubitemid 46055197)
26. Furuya Y, Akakura K,Masai M, ItoH. VitaminD receptor gene polymorphismin Japanese patientswith prostate cancer. Endocr J 1999;46:467-470
27. Gsur A, Madersbacher S, Haidinger G, et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002;51:30-34 (Pubitemid 34274857)
28. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int 2002;68:226-231 (Pubitemid 34621757)
29. Huang SP, Huang CY, Wu WJ, et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006;119:1902-1907
30. Keitheri Cheteri MB, Stanford JL, Friedrichsen DM, et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004; 59:409-418 (Pubitemid 38661808)
31. Liu JH, Li HW, Tong M, Li M, Na YQ. Genetic risk factors of prostate cancer in Han nationality population in northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer. Zhonghua Yi Xue Za Zhi 2004;84:364-368
32. Suzuki K, Matsui H, Ohtake N, et al. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 2003;10:261-266 (Pubitemid 36609464)
33. Williams H, Powell IJ, Land SJ, et al. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate 2004;61:267-275 (Pubitemid 39350450)
34. Huang SP, Chou YH, Wayne Chang WS, et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004;207:69-77. (Pubitemid 38429888)
35. Donovan J,Hamdy F, NealD, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003;7:1-42.
36. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002;94:2511-2516 (Pubitemid 34457134)
37. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265 (Pubitemid 40202029)
38. Sinnwell JP, Schaid DJ. Haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous: R package version 1.2.2; 2005.
39. Luscombe CJ, French ME, Liu S, et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001;85:1504-1509 (Pubitemid 34001581)
40. Chokkalingam AP, McGlynn KA, Gao YT, et al. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res 2001; 61:4333-4336
41. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
42. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101
43. Yu K,Wang Z, Li Q, et al. Population substructure and control selection in genome-wide association studies. PLoS ONE 2008;3:e2551.
44. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7:385-390 (Pubitemid 28354126)
45. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313-1316 (Pubitemid 34522785)
46. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451 (Pubitemid 27208886)
47. 3 substages for the prediction of biochemical recurrence after radical prostatectomy. Cancer 2006;106:775-782
48. Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the vitaminDpathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1990-1999
49. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864